Kyntra Bio, Inc. (KYNB)
6.31
-0.19
(-2.92%)
USD |
NASDAQ |
Oct 02, 16:00
6.30
-0.01
(-0.16%)
After-Hours: 20:00
Kyntra Bio Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -10.03% |
| December 31, 2025 | 77.60% |
| September 30, 2025 | 87.55% |
| June 30, 2025 | 77.30% |
| March 31, 2025 | 78.86% |
| December 31, 2024 | |
| September 30, 2024 | -439.8% |
| June 30, 2024 | 7.72% |
| March 31, 2024 | 15.85% |
| December 31, 2023 | 41.04% |
| September 30, 2023 | 89.43% |
| June 30, 2023 | 87.12% |
| March 31, 2023 | 90.35% |
| December 31, 2022 | 85.67% |
| September 30, 2022 | 72.62% |
| June 30, 2022 | 77.16% |
| March 31, 2022 | 93.03% |
| December 31, 2021 | 65.50% |
| September 30, 2021 | 96.24% |
| June 30, 2021 | 69.73% |
| March 31, 2021 | 77.26% |
| December 31, 2020 | 87.53% |
| September 30, 2020 | 82.33% |
| June 30, 2020 | 79.95% |
| March 31, 2020 | 73.64% |
| Date | Value |
|---|---|
| December 31, 2019 | 25.71% |
| September 30, 2019 | 81.87% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 94.45% |
| June 30, 2018 | 96.44% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 96.28% |
| June 30, 2017 | 94.89% |
| March 31, 2017 | 86.16% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
| June 30, 2013 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Vericel Corp. | 72.82% |
| Nektar Therapeutics | 98.46% |
| Capricor Therapeutics, Inc. | -- |
| ARS Pharmaceuticals, Inc. | 61.83% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -23.95% |
| Profit Margin (Quarterly) | -812.3% |
| Return on Net Operating Assets | -533.1% |